Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab with Embolization in Metastatic RCC
NCT04429321Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Aug 2020
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in renal cell carcinoma (RCC), sponsored by Abramson Cancer Center. Primary endpoint: Rate of serious adverse events. Started Aug 2020; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04429321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429321.